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Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.018MicroRNAs (miRNAs) are endogenous, 21- to 23-nucleotide-
long RNA molecules that post-transcriptionally regulate
target genes. miRNAs interact specifically with certain
mRNAs by repressing their translation or inducing their
degradation (1). Current estimates are that miRNAs
hereby regulate the levels of the majority of mammalian
roteins (2). Research in recent years has assigned miRNAs
key regulatory role in various physiological processes. Also,
growing number of miRNAs has been implicated in the
athogenesis of several diseases, including cardiac disease
3). With respect to the latter, miRNAs have been impli-
ated in cardiac hypertrophy (4,5), fibrosis (6), and vascular
isease (7). Intriguingly, miRNAs also appear to represent
alid therapeutic targets, because modulation of their ex-
ression in vivo (for example, with antisense RNA mole-
ules) has been shown to effectively modulate cardiovascular
isease in various animal models (4,6,8–10). Most recently,
iRNAs have received much attention regarding their
uitability as biomarkers for disease. Following pioneering
ork from the cancer field (11,12), also several cardiovas-
ular studies have found marked deregulation of miRNAs in
arious types of clinical specimens (for review, see ref. 13).
See page 290
What is the advantage of measuring levels of circulating
miRNAs, given the wealth of information on protein
biomarkers? There are several reasons. 1) As nucleic acids,
miRNAs can be both amplified and detected with high
sensitivity and specificity. 2) miRNA arrays and quantitative
PCR (qPCR) methodology allow the quantification of
many miRNAs in a single experiment. There is evidence
that the combined analysis of miRNAs and their coexpres-
sion pattern (miRNA networks) enhances the predictive
power. 3) miRNAs are relatively stable over time in human
blood and appear to be protected from degradation through
various mechanisms.
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in material such as blood and urine has certain disadvan-
tages: 1) The concentrations of most circulating miRNAs
are typically very low, which makes reliable quantitation
and normalization a challenge with existing technology.
Also, there is no consensus for normalization controls.
2) Current qPCR and microarray technologies are still
time-consuming (several hours) compared with some
protein-based biomarker tests such as troponin or
C-reactive protein, which offer results within minutes.
3) For now, the added value of miRNA-based biomarkers
remains to be established by more rigorous testing and
comparison to established biomarkers. Despite these
hurdles, several laboratories have already obtained pro-
files of circulating miRNAs in cardiovascular disease and
explored their biomarker potential (see Table 1 for an
overview [14–24]). What is immediately apparent, are
certain inconsistencies between studies, where the same
or highly similar settings have been studied. This can be
partially attributed to the current immaturity of the field,
which still includes technical issues such as variability of
RNA extraction protocols, different means of nucleic acid
detection and normalization procedures. However, many
studies are simply underpowered (too low numbers of
patients) and/or do not use appropriate controls matched
for potentially confounding factors such as age, sex,
medication, and comorbidities. Also, there is little com-
parison of miRNAs to reference biomarkers.
It is against this background that Zampetaki et al. (24)
report in this issue of the Journal the first prospective cohort
on the determination of circulating miRNAs in cardiovas-
cular disease. Their study design should set the bar markedly
higher for future studies on miRNAs as biomarkers for
cardiovascular disease. As a continuation of a similar study
on type 2 diabetes (25), Zampetaki et al. (24) have now
quantified 19 circulating miRNAs in 820 participants of
a population-based study in Bruneck, Italy. Among these,
3 miRNAs (namely, miR-126, miR-197, and miR-223)
are reported to be significantly associated with the risk of
future myocardial infarction. This association resulted
from multivariable statistical analysis (i.e., multiple po-
tentially confounding parameters were taken into ac-
count). Importantly, the authors report that the combi-
nation of these 3 miRNAs improves the Framingham
Risk Score for hard coronary heart disease, which is based
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ensity lipoprotein cholesterol, blood pressure, and smoking
tatus (26). The improvement of risk classification amounted
o nearly 15%, which is remarkable and exceeded the
mpact of alternative candidate biomarkers such as C-reactive
rotein.
A second part of this work aims to provoke changes in
lasma miRNA levels through a controlled intervention in
ealthy volunteers. The intervention consisted of 30 min of
high cuff inflation resulting in leg ischemia and repetitive
ampling post-injury. Although this model cannot mimic
he situation of incident MI in the Bruneck cohort, the
esults support coregulation of these 3 miRNAs because
hey were all up-regulated in plasma alongside 2 additional
iRs, miR-21, and miR-24.
What are the principal merits of this study? 1) This
Selected Studies of Plasma/Serum miRNAs in CHDTable 1 Selected Studies of Plasma/Serum miRNAs in CHD
Disease (n) Controls (n)
miRs
Plasma
Case-control studies, cross-sectional
CHD (36) Healthy (17) Down: m
-155,
CHD (31) Non-CHD (14) Up: miR-
Down: m
-155
AMI (19) CHD non-AMI (31) Up: miR-
-499
No CHD (7)
AMI (33) Healthy (30)
CV disease other (17)
CHD non-AMI (16)
Up: miR-
AMI (33) Healthy (17) Up: miR-
Down: m
AMI (9)
UAP (5)
Healthy (10) Up: miR-
AMI (93) Healthy (66) Up: miR-
AMI (31) Healthy (20) Up: miR-
ACS (29) Non-ACS (42) Up. miR-
AMI (32) Chest pain, non-AMI (36) Up: miR-
Down: m
ACS cohort STEMI (196),
NSTEMI (131)
UAP (117) Up: miR-
Cohort (n) Incident Event
miRs W
Prospective studies
ACS cohort (444) Death (34) Up: miR-
Bruneck cohort (820) AMI (47) Up: miR-
Down: m
ACS  acute coronary syndrome(s); AMI  acute myocardial infarction; CHD  coronary heart dis
V  cardiovascular disease; hsTnT  high-sensitivity troponin T; ROC  receiver-operating cha
yocardial infarction; TnI  troponin I; TnT  troponin T; UAP  unstable angina pectoris.tudy provides for the first time an miRNA-based bio-marker signature for cardiovascular disease that adds
predictive power to an established standard, in this case,
the Framingham Risk Score for hard coronary heart
disease. 2) The study is performed in a prospective,
population-based cohort. The results of this type of
studies can be expected to be more robust than those of
studies using healthy controls. 3) The intervention part in
healthy volunteers provides interesting clues with regard
to the potential origin of some biomarker miRNAs. With
regard to the latter, the concomitant increase in miR-
126, miR-197, and miR-223 during thigh cuff ischemia
raises several interesting questions: From where do these
miRNAs originate? How are they transported and stabi-
lized in the blood? Are they taken up by target cells? If
yes, by what mechanisms and by what cell type? Are the
concentrations in plasma and in potential target cells
Altered Serum/
ntration in Disease Comparison With Established Biomarker Ref. #
-92a, -126, -145, — 14
-92a, -126, -145,
6, -133a, -208a, Correlation of hsTnT with miR-133a, -499 15
a, -208a, -499 TnT 16
a, -133b, -499-5p — 17
, -375
— 18
QRS duration, no correlation with TnI,
CK-MB
ROC analysis
19
CK-MB 20
a Correlation with CPK, CK-MB and
cTnT
ROC analysis
21
-208b, -499 Correlation of miR-208b and -499 with
TnT
22
ROC analysis
a, -208b Correlation of hsTnT with 1, miR-133a,
-133b, -208b
23
redictive Value for
ent Event
Predictive Value in Addition to
Established Biomarker Ref. #
-208b None in addition to hsTnT 23
Predictive value in addition to
Framingham Risk Score
24
, -223
-MB creatine kinase myocardial band; CPK creatine phosphokinase; cTnT cardiac troponin T;
tic; NSTEMI  non–ST-segment elevation myocardial infarction; STEMI  ST-segment elevationWith
Conce
iR-17,
-199a
133a
iR-17,
92, -12
1, -133
1, -133
iR-122
499
1
1
1, -133
133a,
iR-223
1, -133
ith P
Incid
133a,
126
iR-197
ease; CKsufficiently high to exert biological effects? Most of these
302 Engelhardt JACC Vol. 60, No. 4, 2012
Small RNA Biomarkers Come of Age July 24, 2012:300–3questions are, to date, unanswered. Recent studies have
suggested that miRNAs are circulating in exosomes,
microparticles, and apoptotic bodies shedding from en-
dothelial cells, platelets, and cardiomyocytes (27). The present
work seems to confirm that notion, given the significant
correlation between the concentration of the plasma
miRNAs and the count of platelet microparticles. Be-
cause endothelial cells express very high levels of miR-
126 (more than platelets), it would be interesting to know
the relative contribution of endothelial cell– derived and
platelet-derived microparticles to miR-126 plasma levels.
Therefore, an inventory of the various circulating micro-
particles (28) with regard to their miRNA content is
needed to advance the field. The data from Zampetaki et
al. (24) suggest that platelets and endothelial cells are the
likely source for microparticles containing miR-126,
miR-197, and miR-223. An interesting question is
whether these miRs exert biological effects once they
leave their cells of origin. Several recent studies suggest
that this might in fact be the case suggesting that plasma
miR-126 is taken up by the vasculature at sites of injury
(15,29).
The expression data of miRs in platelets again reminds us
of how little we know about their function in platelets.
Platelets are anuclear and as such do not carry out transcrip-
tion (except from their mitochondrial DNA), but they
contain considerable amounts of mRNAs, which have been
shown to be subject to miRNA-based regulation (30). The
function of the major platelet miRNAs with regard to their
role in platelet biology and platelet-related diseases must be
investigated in future studies.
This study clearly represents a step forward toward a
critical assessment of circulating miRNAs as biomarkers for
disease. Inevitably, it also has limitations. First, despite a
considerable size of the study cohort, the total number of
incident cases of myocardial infarction is relatively low.
Second, only a predefined panel of miRNAs was analyzed in
all participants. This panel was initially chosen based on
pattern analysis of miRNA expression in a smaller subpop-
ulation and then applied to the entire cohort. Important
candidates (e.g., miRNAs) that only show deregulation in
cases of incident MI may have been overlooked. Third, the
present findings await confirmation in an independent
cohort before one may proceed to make use of these
miRNAs as useful tools to enhance risk stratification for
myocardial infarction.
Taken together, this study is evidence that the field of
miRNAs as biomarkers is about to mature. Work such as
that by Zampetaki et al. (24) will show in the not too distant
future whether quantitation of these tiny RNA molecules
will eventually prove useful as biomarkers for clinical prac-
tice. Whether the sparse concentrations of miRs present in
the circulation exert a functional role is an interesting, yet
even more challenging question.Reprint requests and correspondence: Dr. Stefan Engelhardt,
Institute of Pharmacology and Toxicology, Technische Universi-
taet Muenchen (TUM), Biedersteiner Strasse 29, 80802 Munich,
Germany. E-mail: stefan.engelhardt@tum.de.
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